[go: up one dir, main page]

PA8800101A1 - SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND - Google Patents

SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND

Info

Publication number
PA8800101A1
PA8800101A1 PA20088800101A PA8800101A PA8800101A1 PA 8800101 A1 PA8800101 A1 PA 8800101A1 PA 20088800101 A PA20088800101 A PA 20088800101A PA 8800101 A PA8800101 A PA 8800101A PA 8800101 A1 PA8800101 A1 PA 8800101A1
Authority
PA
Panama
Prior art keywords
solid dispersion
aril
urea
based compound
product containing
Prior art date
Application number
PA20088800101A
Other languages
Spanish (es)
Inventor
Schroeder Rudolf
Heitermann Tanjia
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PA8800101A1 publication Critical patent/PA8800101A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PRODUCTO DE DISPERSIÒN SÒLIDA QUE COMPRENDE AL MENOS UN AGENTE FARMACÈUTICAMENTE ACTIVO A BASE DE N-ARIL UREA O UN AGENTE DE ESTRUCTURA RELACIONADA QUE ES OBTENIDO MADIANTE A) LA PREPARACIÒN DE UNA MEZCLA LIQUIDA QUE CONTIENE EL AL MENOS UN AGENTE ACTIVO, EL AL MENOS UN TENSIOACTIVO ACEPTABLE PARA USO FARMACÈUTICO Y EL AL MENOS UN SOLVENTE, Y B) LA ELIMINACIÒN DEL O DE LOS SOLVENTES DE LA MEZCLA LÌQUIDA PARA OBTENER EL PRODUCTO DE DISPERCIÒN SÒLIDA.A SOLID DISPERSION PRODUCT THAT INCLUDES AT LEAST A PHARMACUTICALLY ACTIVE AGENT BASED ON N-ARIL UREA OR A RELATED STRUCTURE AGENT THAT IS OBTAINED BY MEANS OF A) THE PREPARATION OF A LIQUID MIXTURE THAT CONTAINS AT LEAST AN ATTENDED AGENT AN ACCEPTABLE TENSIOACTIVE FOR PHARMACEUTICAL USE AND THE AT LEAST ONE SOLVENT, AND B) THE ELIMINATION OF THE SOLVENTS OR THE MIXTURE MIXED TO OBTAIN THE PRODUCT OF SOLID DISPERSION.

PA20088800101A 2007-10-19 2008-10-17 SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND PA8800101A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PA8800101A1 true PA8800101A1 (en) 2009-05-15

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088800101A PA8800101A1 (en) 2007-10-19 2008-10-17 SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND

Country Status (18)

Country Link
EP (1) EP2197425A2 (en)
JP (1) JP2011500649A (en)
KR (1) KR20100087170A (en)
CN (1) CN101827584A (en)
AU (1) AU2008313622A1 (en)
BR (1) BRPI0818340A2 (en)
CA (1) CA2699301A1 (en)
CO (1) CO6270206A2 (en)
CR (1) CR11442A (en)
DO (1) DOP2010000117A (en)
EC (1) ECSP10010183A (en)
GT (1) GT201000102A (en)
MX (1) MX2010004291A (en)
PA (1) PA8800101A1 (en)
RU (1) RU2010119929A (en)
UA (1) UA100865C2 (en)
WO (1) WO2009050291A2 (en)
ZA (1) ZA201002095B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
UA108886C2 (en) 2010-06-09 2015-06-25 Еббві Бахамаз Лтд. SOLID DISPERSIONS CONTAINING KINAS INHIBITORS
CN108542906A (en) 2011-11-11 2018-09-18 诺华股份有限公司 The method for treating proliferative disease
UA115039C2 (en) * 2011-11-23 2017-09-11 Еррей Біофарма Інк. Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346128B (en) * 2005-10-25 2013-10-02 雅培制药有限公司 Formulation comprising drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
UA100865C2 (en) 2013-02-11
EP2197425A2 (en) 2010-06-23
CR11442A (en) 2010-09-06
DOP2010000117A (en) 2010-05-15
CO6270206A2 (en) 2011-04-20
WO2009050291A2 (en) 2009-04-23
CN101827584A (en) 2010-09-08
ECSP10010183A (en) 2010-06-29
CA2699301A1 (en) 2009-04-23
GT201000102A (en) 2012-03-12
AU2008313622A1 (en) 2009-04-23
ZA201002095B (en) 2011-11-30
KR20100087170A (en) 2010-08-03
BRPI0818340A2 (en) 2015-04-22
MX2010004291A (en) 2010-08-02
WO2009050291A3 (en) 2010-04-08
RU2010119929A (en) 2011-11-27
JP2011500649A (en) 2011-01-06

Similar Documents

Publication Publication Date Title
GT201000095A (en) SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND
PA8800101A1 (en) SOLID DISPERSION PRODUCT CONTAINING A N-ARIL UREA-BASED COMPOUND
AR051969A1 (en) METHODS AND COMPOSITIONS THAT USE IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
AR083016A1 (en) LIQUID FORMULATIONS FOR AGRICULTURE WITH BETTER STABILITY
AR086115A1 (en) IMPROVED PARENTERAL FORMULATIONS OF LIPOFIL PHARMACEUTICAL AGENTS AND METHODS FOR THE PREPARATION AND USE OF THE SAME
AR047928A1 (en) TETRAHYDROPIRIDOINDOL DERIVATIVES
UY28342A1 (en) NEW COMPOUNDS
BR112014027039A2 (en) non-aqueous topical pharmaceutical formulation; use of non-aqueous pharmaceutical formulation; non-aqueous formulation; and method
CO6251200A2 (en) METHOD FOR MODULATING THE MICROENCAPSULATED ACTIVE INGREDIENT RELEASE RATE USED FOR CULTURE PROTECTION
CL2011001464A1 (en) Purine derived compounds, cb2 receptor agonists; pharmaceutical composition that includes them; and use of the compound to treat osteoarthritic pain.
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
DK2046292T3 (en) Formulations for benzimidazolylpyridyl ethers
BRPI0719277A2 (en) CONCENTRATED PHYTOSANITARY FORMULATION, USING FORMULATION AND SOLVENT COMPOSITION UNDERSTANDING A SOLVENT MIX
PA8577201A1 (en) 3-PHENYL-PROPIONAMIDE, 3-PHENYL-ACRYLAMID AND DERIVATIVES 3-PHENYL-PROPINAMID AS MAO-B INHIBITORS
CL2007002754A1 (en) EMULSIONING COMPOSITION OF ACTIVE, TENSOACTIVE AGROCHEMICALS, AROMATIC SOLVENTS, PROPYLENE GLYCOL DIACETATE, 1,3-DIMETHYL-2-IMIDAZOLIDINONE AND FORMULATION AUXILIARIES; SOLVENT FOR AGROCHEMICAL COMPOUNDS; DILUTION UNDERSTANDING THE COMPOSITION
CL2012000374A1 (en) Method for the preparation of an active flavoring composition that comprises a first reaction between an amino compound and a carbonyl, resulting in a first mixture of intermediates, a second reaction with a second amino compound alone or in combination with a carbinyl compound, resulting in a second mixture of intermediates, additional serial reactions with compounds of other chemical classes, last reaction comprising a mixture of all of the above intermediate mixtures.
UY28366A1 (en) CHEMICAL COMPOUNDS
CL2007002970A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
CO6351722A2 (en) UREA HETEROCICLICAL DERIVATIVES AND THEIR EMPLOYMENT METHODS
CL2007001981A1 (en) COMPOSITION THAT INCLUDES AT LEAST ONE AGROCHEMICAL ACTIVE PRINCIPLE OF THE PIRETROID GROUP, AT LEAST A TENSIOACTIVE, AND AT LEAST A SOLVENT NOT MISSIBLE IN WATER; PROCEDURE FOR THE FIGHT AGAINST ANIMAL PESTS; AND ITS USE.
AR052787A1 (en) PROCESS TO PREPARE FORMULATIONS OF LIPOFILIC ACTIVE SUBSTANCES THROUGH ATOMIZATION LIOPHILIZATION
CL2011001207A1 (en) Extrudates containing at least one needle-shaped pharmaceutically active substance, such that the ratio between the particle size of the needle-shaped pharmaceutically active substance and the diameter of the chain is at least 1:20; pharmaceutical composition; and its use to prepare medicines.
CL2008001650A1 (en) Procedure for preparing a solution of docetaxel in polysorbate 80 that consists of dissolving the docetaxel in an organic solvent that has a boiling point between 40-153 degrees Celsius, with the exception of ethanol, the solution is mixed with polysorbate 80, evaporates solvent under reduced pressure.
CL2009001370A1 (en) Crystalline forms of (r, s) -, (r) - and (s) -dopc; Preparation process; pharmaceutical composition; and its use to prepare medicines.